Scotia Capital Inc. Acquires 3,771 Shares of Illumina, Inc. (NASDAQ:ILMN)

Scotia Capital Inc. lifted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 30.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 16,315 shares of the life sciences company’s stock after purchasing an additional 3,771 shares during the quarter. Scotia Capital Inc.’s holdings in Illumina were worth $2,180,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Wellington Management Group LLP lifted its position in Illumina by 2.5% in the 3rd quarter. Wellington Management Group LLP now owns 30,946 shares of the life sciences company’s stock valued at $4,036,000 after acquiring an additional 755 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Illumina in the third quarter valued at about $226,000. MML Investors Services LLC boosted its position in shares of Illumina by 4.4% during the third quarter. MML Investors Services LLC now owns 23,373 shares of the life sciences company’s stock worth $3,048,000 after buying an additional 990 shares during the period. Geode Capital Management LLC grew its holdings in shares of Illumina by 1.8% during the third quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock worth $354,933,000 after buying an additional 48,018 shares in the last quarter. Finally, Toronto Dominion Bank raised its position in Illumina by 38.5% in the 3rd quarter. Toronto Dominion Bank now owns 30,838 shares of the life sciences company’s stock valued at $4,022,000 after buying an additional 8,578 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently weighed in on ILMN. Piper Sandler raised their price target on shares of Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Guggenheim decreased their target price on shares of Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Stephens reissued an “overweight” rating and set a $156.00 price target on shares of Illumina in a research report on Tuesday, March 11th. Citigroup decreased their price objective on Illumina from $90.00 to $85.00 and set a “neutral” rating for the company in a report on Monday, April 7th. Finally, Robert W. Baird dropped their target price on Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a report on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $138.70.

Illumina Stock Up 4.9 %

Illumina stock opened at $74.78 on Friday. The company’s 50-day moving average price is $88.58 and its two-hundred day moving average price is $122.32. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The stock has a market cap of $11.85 billion, a P/E ratio of -9.74, a P/E/G ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.